Protease resistant modified erythropoietin polypeptides
US8114839B2 · kind B2 · utility
1Cited by
69References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 6, 2008 |
| Grant date | Feb 14, 2012 |
| Priority date | — |
| Expiry date | Jun 6, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Modified erythropoietin polypeptides that include the mutation R131Q, and uses thereof are provided. Also provided are pharmaceutical compositions, including compositions formulated for oral administration, that contain the modified erythropoietin polypeptides and uses of the compositions to treat diseases and conditions treated by erythropoietin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.